Skip to main content
Figure 1 | BMC Health Services Research

Figure 1

From: A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand

Figure 1

All available interventions compared with palliative care. Scenario 1=Adding the second drug when drug resistance occurred; Scenario 2= Adding a more potent drug without cross-resistance when the HBV DNA level more than 60 IU/ml at week 24 based on the road map guideline; LMV=Lamivudine; ADV=Adefovir; ETV=Entecavir; TVD=Telbivudine; PEG=Pegylated interferon.

Back to article page